- Stocks
- Healthcare
- NASDAQ: EDIT

Price (delayed)

$10.06

Market cap

$823.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$735.93M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a

EDIT's EPS is up by 37% year-on-year and by 25% since the previous quarter

Editas Medicine's net income has increased by 30% YoY and by 21% QoQ

The debt has contracted by 17% YoY but it has grown by 6% from the previous quarter

Editas Medicine's quick ratio has decreased by 12% QoQ and by 9% YoY

EDIT's equity is down by 3.2% year-on-year and by 3.2% since the previous quarter

What are the main financial stats of EDIT

Market
Valuations
Earnings

Shares outstanding

81.81M

Market cap

$823.05M

Enterprise value

$735.93M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.35

Price to sales (P/S)

9.78

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

9.42

Revenue

$78.12M

EBIT

-$170.79M

EBITDA

-$164.72M

Free cash flow

-$136.9M

Per share
Balance sheet
Liquidity

EPS

-$2.02

Free cash flow per share

-$1.8

Book value per share

$4.27

Revenue per share

$1.03

TBVPS

$6.57

Total assets

$499.15M

Total liabilities

$150.06M

Debt

$36.54M

Equity

$349.1M

Working capital

$277.61M

Debt to equity

0.1

Current ratio

5.39

Quick ratio

5.27

Net debt/EBITDA

0.53

Margins
Efficiency
Dividend

EBITDA margin

-210.8%

Gross margin

100%

Net margin

-196.1%

Operating margin

-216.6%

Return on assets

-30.5%

Return on equity

-43%

Return on invested capital

-50%

Return on capital employed

-39.2%

Return on sales

-218.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Editas Medicine stock price performed over time

Intraday

-9.12%

1 week

26.86%

1 month

31.85%

1 year

11.28%

YTD

-0.69%

QTD

-0.69%

How have Editas Medicine's revenue and profit performed over time

Revenue

$78.12M

Gross profit

$78.12M

Operating income

-$169.18M

Net income

-$153.22M

Gross margin

100%

Net margin

-196.1%

The net margin has soared by 82% YoY and by 75% from the previous quarter

EDIT's operating margin has surged by 81% year-on-year and by 74% since the previous quarter

Editas Medicine's net income has increased by 30% YoY and by 21% QoQ

EDIT's operating income is up by 25% year-on-year and by 19% since the previous quarter

What is Editas Medicine's growth rate over time

What is Editas Medicine stock price valuation

P/E

N/A

P/B

2.35

P/S

9.78

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

9.42

EDIT's EPS is up by 37% year-on-year and by 25% since the previous quarter

EDIT's P/B is 41% below its 5-year quarterly average of 4.0 but 31% above its last 4 quarters average of 1.8

EDIT's equity is down by 3.2% year-on-year and by 3.2% since the previous quarter

How efficient is Editas Medicine business performance

EDIT's return on sales has surged by 81% year-on-year and by 74% since the previous quarter

Editas Medicine's ROA has increased by 22% YoY and by 21% from the previous quarter

The ROE has increased by 21% from the previous quarter and by 15% YoY

EDIT's return on invested capital is up by 20% year-on-year and by 18% since the previous quarter

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

How did Editas Medicine financials performed over time

The current ratio has contracted by 12% from the previous quarter and by 9% YoY

Editas Medicine's quick ratio has decreased by 12% QoQ and by 9% YoY

The debt is 90% less than the equity

The debt has contracted by 17% YoY but it has grown by 6% from the previous quarter

The company's debt to equity fell by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.